These results indicate that concurrent inhibition of activin-class ligands and blockade of inflammatory processes by ActRIIA-Fc leads to persistent reversal of cardiopulmonary structural remodeling in severe experimental PAH, even in the apparent absence of actively circulating therapeutic molecules. This evidence concerns the gene INHBE and pulmonary arterial hypertension.